
CareDx (CDNA) Stock Forecast & Price Target
CareDx (CDNA) Analyst Ratings
Bulls say
CareDx is a strong performing precision medicine company with a wide range of testing services and products focused on the transplant patient journey. Their recent acquisition and sale of businesses are expected to positively impact revenue, and they have a strong pipeline of potential products in development. Their recent financial performance has been strong, and the company is confident in its ability to continue growing and gaining market share in the coming years.
Bears say
CareDx is poised for strong and continued growth, with a 50% increase in sales force and improved RCM initiatives leading to increased volumes. The company has established long-term targets for revenue, GM, and EBITDA margin that exceed analyst expectations. With potential adoption of AlloSure Kidney, AlloMap Heart, and the upcoming launch of AlloHeme targeting a $1B TAM and investments in Epic integration, CDNA is making strategic moves to expand its presence in the precision medicine market. However, clinicians and healthcare administrators may be slow to adopt new products, and CDNA's aggressiveness in acquisitions may impact its stock price.
This aggregate rating is based on analysts' research of CareDx and is not a guaranteed prediction by Public.com or investment advice.
CareDx (CDNA) Analyst Forecast & Price Prediction
Start investing in CareDx (CDNA)
Order type
Buy in
Order amount
Est. shares
0 shares